FDA approves first and only oral growth inhibitor MYCAPSSA capsule for the treatment of limb hypertrophy

Chiasma announced that the U.SFood and DrugAdministration,
Fda administration(
FDA) approved its MYCAPSSA (octreotide) capsules for long-term maintenance therapy for patients with amputees and urethra patients who are effective and resistant to the treatment of octreotideMYCAPSSA is the first and only FDA-approved oral growth inhibitor analogue (SSA) and the first FDA-approved product to use Chiasma's instantaneous permeability enhancer (TPE) technologyamplifying hypertrophy is a rare chronic disease, usually caused by benign tumors of the pituitary gland, characterized by excessive production of growth hormone and insulin-like growth factor-1 hormones, which usually require long-term intensive injection therapyThe company estimates that about 8,000 patients in the U.Sare receiving injectable SSA therapyJill Sisco, president of Acromegaly Community, said: "Patients with terminal hypertrophy face many injectable-related challenges and need new treatment optionsThe entire group of people with limb hypertrophy has been waiting for oral therapy, and the FDA has approved the first oral SSA treatment, which is likely to have a significant impact on the lives of patients with limb hypertrophy and their caregiversLead researcher dr Susan Samson,CHIASMA OPTIMAL clinical trial, said: "Key Phase 3 CHIASMA OPTIMAL trial data show that patients treated with MYCAPSSA were able to maintain average IGF-1 levels within the normal range at the end of the trial, and we believe that oral octade capsules are significant and will address long-term unmet treatment needs." "